Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature

Immune checkpoint blockade including programmed cell death 1 pathway inhibition with agents such as nivolumab is gaining ground in a wide array of malignancies, so far demonstrating significantly improved survival rates even in metastatic, often multiply pretreated settings. Although targeted in nat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastrisiou, Myrto, Kostadima, Fereniki-Lida, Kefas, Aristides, Zarkavelis, George, Kapodistrias, Nikos, Ntouvelis, Evangelos, Petrakis, Dimitrios, Papadaki, Alexandra, Vassou, Amalia, Pentheroudakis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640091/
https://www.ncbi.nlm.nih.gov/pubmed/29067215
http://dx.doi.org/10.1136/esmoopen-2017-000217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640091/
https://www.ncbi.nlm.nih.gov/pubmed/29067215
http://dx.doi.org/10.1136/esmoopen-2017-000217

Ejemplares similares